GeneDx (Nasdaq: WGS), a Stamford, CT-based firm which focuses on delivering improved well being outcomes by genomic insights, acquired Material Genomics, an Oakland, CA-based firm which focuses on AI-powered genomic interpretation.
Beneath the phrases of the settlement, and topic to the phrases and circumstances thereof, GeneDx pays as much as an combination of $33 million in money upon closing with complete consideration doubtlessly as much as an combination of $51 million upon achievement of sure milestones.
The acquisition is anticipated to shut within the second quarter of 2025, topic to closing circumstances.
The acquisition will consolidate GeneDx’s place within the subsequent section of genomic drugs: decentralized testing with centralized intelligence.
Material Genomics is a genomics-driven precision drugs firm offering scientific resolution help software program that permits scientific labs, hospital techniques and country-sequencing applications to achieve actionable genomic insights, leading to extra correct diagnoses and lowered turnaround time. Its end-to-end genomic evaluation platform incorporates AI algorithms, and has functions in each hereditary illness and oncology.
FinSMEs
16/04/2025
